Guangdong Taienkang Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Guangdong Taienkang Pharmaceutical Co., Ltd.

Why is Guangdong Taienkang Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -4.09% and Operating profit at -131.56% over the last 5 years

The company has declared Negative results for the last 10 consecutive quarters

NET PROFIT(9M) At CNY 19.99 MM has Grown at -62.86%
INTEREST(HY) At CNY 9.21 MM has Grown at 94.41%
OPERATING CASH FLOW(Y) Lowest at CNY -12.87 MM

With ROE of 0.79%, it has a very expensive valuation with a 6.52 Price to Book Value

Over the past year, while the stock has generated a return of -26.83%, its profits have fallen by -88.7%

Below par performance in long term as well as near term

Along with generating -26.83% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Guangdong Taienkang Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Guangdong Taienkang Pharmaceutical Co., Ltd.

-26.83%

1.33

46.98%

China Shanghai Composite

21.22%

1.59

13.38%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.09%

EBIT Growth (5y)

-131.56%

EBIT to Interest (avg)

28.35

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.18

Sales to Capital Employed (avg)

0.35

Tax Ratio

4.49%

Dividend Payout Ratio

73.96%

Pledged Shares

Institutional Holding

ROCE (avg)

10.79%

ROE (avg)

7.23%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

822

Industry P/E

Price to Book Value

6.52

EV to EBIT

-1888.85

EV to EBITDA

257.14

EV to Capital Employed

7.35

EV to Sales

16.55

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.39%

ROE (Latest)

0.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at CNY 25.92 MM

RAW MATERIAL COST(Y)

Fallen by -9.85% (YoY

NET SALES(Q)

Highest at CNY 189.52 MM

-18What is not working for the Company

NET PROFIT(9M)

At CNY 19.99 MM has Grown at -62.86%

INTEREST(HY)

At CNY 9.21 MM has Grown at 94.41%

OPERATING CASH FLOW(Y)

Lowest at CNY -12.87 MM

DEBT-EQUITY RATIO (HY)

Highest at -12.13 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.56 times

Here's what is working for Guangdong Taienkang Pharmaceutical Co., Ltd.

Net Profit

Higher at CNY 25.92 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Sales

Highest at CNY 189.52 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Raw Material Cost

Fallen by -9.85% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Guangdong Taienkang Pharmaceutical Co., Ltd.

Interest

At CNY 9.21 MM has Grown at 94.41%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -12.13 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 1.56 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at CNY -12.87 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)